

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/316,199		ATTY. DOCKET NO.: C1040.70006US00	
				FILING DATE: May 21, 1999		CONFIRMATION NO.: 7506	
				APPLICANT: Michael J. McCluskie et al.			
				GROUP ART UNIT: 1633		EXAMINER: Ileana Popa	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		7,271,156	B2	Krieg et al.	07-18-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		2007-0224210	A1	Krieg et al.	09-27-2007
		2007-0232622	A1	Lipford et al.	10-04-2007
		2008-0009455	A9	Krieg et al.	01-10-2008
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0226649	A1	Schetter et al.	09-18-2008

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
		WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
		WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ARULANANDAM et al., Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999 Jan 21;17(3):252-60.	
		GRDIC et al., The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur J Immunol. 1999 Jun;29(6):1774-84.	
		MARINARO et al., Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol. 1999 Jan 1;162(1):114-21.	
		SIMMONS et al., Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma. J Immunol. 2002 Feb 15;168(4):1804-12.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.